Impact News +++ Agilysys Announces 15th Consecutive Record Revenue Quarter: $79.3M in Fiscal 2026 Q2 (Business Wire) +++ AGILYSYS Aktie -3,43%

BIOMARIN Aktie

>BIOMARIN Aktienkurs

45.91 EUR -2.0% (Tradegate)

Ask: 46.07 EUR / 122 Stück

Bid: 45.72 EUR / 123 Stück

Tagesumsatz: 2468 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

BIOMARIN Aktie über LYNX handeln

Intraday

1 Jahr

>BIOMARIN Performance

1 Woche: -0,8%

1 Monat: +2,3%

3 Monate: -10,4%

6 Monate: -16,1%

1 Jahr: -29,8%

laufendes Jahr: -27,6%

>BIOMARIN Aktie

Name:

BIOMARIN PHAR. DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US09061G1013 / 924801

Symbol/ Ticker:

BM8 (Frankfurt) / BMRN (NASDAQ)

Kürzel:

FRA:BM8, ETR:BM8, BM8:GR, NASDAQ:BMRN

Index:

Webseite:

https://www.biomarin.com/

Profil:

BioMarin Pharmaceutical Inc. is a leading biotechn..
>Volltext..

Marktkapitalisierung:

8995.96 Mio. EUR

Unternehmenswert:

8300.53 Mio. EUR

Umsatz:

2614.84 Mio. EUR

EBITDA:

780.7 Mio. EUR

Nettogewinn:

565.2 Mio. EUR

Gewinn je Aktie:

2.96 EUR

Schulden:

526.19 Mio. EUR

Liquide Mittel:

1043.83 Mio. EUR

Operativer Cashflow:

659.39 Mio. EUR

Bargeldquote:

2.09

Umsatzwachstum:

6.73%

Gewinnwachstum:

132.91%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

BIOMARIN

Letzte Datenerhebung:

27.10.25

>BIOMARIN Kennzahlen

Aktien/ Unternehmen:

Aktien: 192.02 Mio. St.

Frei handelbar: 98.51%

Leerverk. Aktien: 4.43%

Rückkaufquote: -0.19%

Mitarbeiter: 3040

Umsatz/Mitarb.: 0.8 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 78.19%

Bewertung:

KGV: 16.01

KGV lG: 13.67

KUV: 3.45

KBV: 1.72

PEG-Ratio: 0.1

EV/EBITDA: 10.63

Rentabilität:

Bruttomarge: 78.76%

Gewinnmarge: 21.62%

Operative Marge: 27.12%

Managementeffizenz:

Gesamtkaprendite: 9.05%

Eigenkaprendite: 11.62%

>BIOMARIN Peer Group

Es sind 596 Aktien bekannt.

>BIOMARIN Chart & Kurs - NASDAQ

>BIOMARIN News

28.10.25 - 01:21	BioMarin outlines $900M–$935M VOXZOGO 2025 revenue target and plans ROCTAVIAN divestiture amid evolving competitive landscape (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.10.25 - 01:18

Biomarin Up After Q3 Earnings: Here’s Everything You Need to Know (24/7 Wall St.)

BioMarin Pharmaceutical (Nasdaq: BMRN) missed both revenue and earnings estimates in the third quarter, and yet, shares are up 1% in after-hours trading. Let's dig into what happened in the company's third quarter and what it says about the future for the company. The stock closed at $52.67, erasing earlier gains and reflecting investor disappointment despite ... Biomarin Up After Q3 Earnings: Here's Everything You Need to Know The post Biomarin Up After Q3 Earnings: Here's Everything You Need to Know appeared first on 24/7 Wall St.....

28.10.25 - 00:36	BioMarin (BMRN) Q3 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

28.10.25 - 00:30	Compared to Estimates, BioMarin (BMRN) Q3 Earnings: A Look at Key Metrics (Zacks)
	The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....

28.10.25 - 00:00	BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings Estimates (Zacks)
	BioMarin (BMRN) delivered earnings and revenue surprises of +180.00% and -1.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

27.10.25 - 23:01	BioMarin verfehlt Prognosen für Q3 2025 – Aktie gibt nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

27.10.25 - 22:18	BioMarin seeks to divest hemophilia A gene therapy Roctavian (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.10.25 - 22:00	Biomarin Pharmaceutical Posts Q3 Loss (AFX)
	WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) Monday reported third-quarter net loss of $31 million or $0.16 per share, compared to net income of $106 million in the same period last ......

27.10.25 - 21:06	BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update (PR Newswire)
	Raises Full-year 2025 Total Revenues Guidance at the Midpoint; Reaffirms VOXZOGO Full-year Outlook 2025 Year-to-date Total Revenues Increased 11% Y/Y Led by More Than 20% Revenue Growth for PALYNZIQ and VOXZOGO BioMarin Focuses Commercial Portfolio; Pursuing Options to Divest ROCTAVIAN......

27.10.25 - 21:06	BioMarin Pharmaceutical Non-GAAP EPS of $0.12 misses by $0.19, revenue of $776M misses by $4.43M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.10.25 - 17:54	What to Expect from Biomarin Pharmaceutical′s Earnings (Benzinga)
	read more...

22.10.25 - 22:09	BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET (PR Newswire)
	SAN RAFAEL, Calif., Oct. 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, October 27, 2025, at 4:30 p.m. ET to discuss third......

01.10.25 - 17:30	Here′s Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
	Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....

01.10.25 - 09:30

BioMarin: Warum die Aktie jetzt Chancen bietet (Sharedeals)

Die Aktie von BioMarin Pharmaceutical steht derzeit unter Druck, obwohl das Unternehmen kontinuierlich wächst und seine Pipeline vielversprechend ist. An der Börse wird das Papier deutlich unterhalb des Branchendurchschnitts gehandelt, was Anlegern ein attraktives Einstiegsfenster eröffnet. BioMarin hat sich als international führendes Biotech-Unternehmen etabliert, das sich auf Therapien für seltene genetische Krankheiten spezialisiert. Die Produktpalette […] The post BioMarin: Warum die Aktie jetzt Chancen bietet first appeared on sharedeals.de....

19.09.25 - 17:30	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
	The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

15.09.25 - 17:30	Here′s Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

08.09.25 - 22:15	Are Options Traders Betting on a Big Move in BioMarin Pharmaceutical Stock? (Zacks)
	Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately....

08.09.25 - 15:09	BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting (PR Newswire)
	Children who received VOXZOGO showed anatomical improvements in spinal morphology VOXZOGO continued to significantly improve growth in children who received the medicine after puberty onset SAN RAFAEL, Calif., Sept. 8, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today......

06.09.25 - 17:09	BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism (PR Newswire)
	New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ BioMarin's planned submission to global health authorities on track for second half of 2025 SAN RAFAEL, Calif., Sept. 6, 2025 /PRNewswire/ -- BioMarin......

28.08.25 - 17:30	Here′s Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Sich zu mühen und mit dem Widerstande zu kämpfen, ist dem Menschen Bedürfnis wie dem Maulwurf das Graben. - Arthur Schopenhauer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram